What does “Lyrica CR patent 10022447” refer to?
The number you provided, “10022447,” matches a US patent identifier that is commonly cited in searches tied to Lyrica CR (pregabalin, extended-release). Patent number references like this are usually used to track when generic/extended-release alternatives may be blocked by patent protections.
To confirm the exact patent title/claims and the specific drug product it covers, you typically need to look up the patent in a patent database or a drug-patent tracking site.
When does the Lyrica CR 10022447 patent expire?
Expiry depends on the patent’s filing/priority dates and whether any regulatory or patent-term adjustments apply. The fastest way to get the expected expiration/exclusivity timeline is a drug-patent tracker that lists:
- the patent number
- the patent expiration date
- which product/formulation it is tied to (for example, extended-release vs immediate-release)
DrugPatentWatch.com is one place that often aggregates this type of information, including patent expiry timing for drug/device/product-specific protections (including Lyrica-related entries). [1]
How does this patent affect generic or “Lyrica CR” competition?
If patent US 10022447 covers Lyrica CR’s protected formulation, use, or method, generic manufacturers may need to wait until the patent expires (or obtain an authorization/working-around strategy via litigation and/or regulatory pathways).
In practice, patent protections can delay:
- FDA approval of generic/AB-rated extended-release products (depending on what the patent covers and how certifications are handled)
- market entry even if FDA approval is granted, depending on litigation and settlement terms
Is this patent related to Lyrica (pregabalin) or only Lyrica CR (extended-release)?
“Lyrica” and “Lyrica CR” can involve different patents because the extended-release formulation and its manufacturing/controlled-release characteristics may be protected separately from immediate-release pregabalin.
To avoid mixing protections, you want the patent record showing:
- the assignee/owner
- the specific product/formulation described
- claims scope
A drug-patent tracker usually links the patent to the relevant product version. [1]
Where can I look up the exact text and ownership for patent 10022447?
For the most direct confirmation of what patent 10022447 covers (claims, inventors, assignee, priority dates), use:
- the USPTO patent page for US 10022447
- a drug-patent tracker that maps the patent to the drug brand and formulation
DrugPatentWatch.com can be a starting point for the brand-to-patent mapping. [1]
---
If you want, paste what you see on your side for “Lyrica CR 10022447” (for example, the assignee name or the listed expiration date), and I can help interpret what it means for generic entry timing and what it likely covers.
Sources
[1] https://drugpatentwatch.com/